Breadcrumb

[A12-18] Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Overview

Overview

Commission: Commission awarded on 2012-12-14 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 143 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-37] Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A13-18] Addendum to Commission A12-18 (dapagliflozin)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2013-03-15 Extract of dossier assessment 143 kBPDFdownload file
2013-03-15 Dossier assessment (German version) 549 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) [PDF, 143 kB]

Federal Joint Committee (G-BA)

2013-06-06 A G-BA decision was published.

G-BA documents on this decision (German only)

Press releases

2013-03-15 Added benefit of dapagliflozin is not proven



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close